On Jan. 27 I issued a buy recommendation on Synergy Pharmaceuticals (NSDQ: SGYP), a biotech company focusing on diseases and conditions of the digestive system. The company received FDA approval for its idiopathic (cause unknown) constipation drug Trulance on Jan. 19, ten days ahead of the deadline—a bullish sign. … Read More
Robert Frick is Editorial Director of Investing Daily. Bob is a career business and financial journalist, with a 15-year tenure as senior editor for Kiplinger’s Personal Finance magazine, in addition to working as a newspaper business writer and editor, and a stint as an investment writer for USA Today.
He’s a nationally recognized authority on behavioral finance, and worked two years as a writer, researcher and speaker for the Allianz Global Investors Center for Behavioral Finance.
He has co-authored three books on personal finance, and holds an M.B.A. and a B.A. (Journalism) from the Pennsylvania State University
Analyst Articles
Dear Breakthrough Tech Profits Subscriber,This is Robert Frick, editorial director of Investing Daily. Recently we added a new service to your BTP subscription. This service gives you recommendations on private companies, and shows you, step-by-step, how to invest in them.These companies can yield impressive returns – sometimes 10 times to 15 times… Read More
The stock market’s reaction to Donald Trump’s upset victory has been calmer than expected. But while the broad indices haven’t freaked out, certain sectors of the market have seen big movements.We’ve talked about big moves among pharmaceutical and hospital stocks, as well as in the technology sector. Shares… Read More
On Sept. 16 I recommended Buy to open the January 20, 2017 call on Mylan (MYL) with a strike price of $45 at $1.90 or lower. Symbol (MYL170120C45). Since that recommendation Mylan hit more rough waters. However, Mylan bounced 8% on Monday on the heels of a $465 million settlement with the Department… Read More
Sell to close the Nov. 18, 2016 put on VF Corporation (VFC) with a strike price of $62.50 at $4.40 or higher for an 80% gain. Symbol (VFC161118P62.5)When we bought these puts less than 3 weeks ago we expected to hold them for a longer period of time. However the… Read More
We are selling Express (NYSE: EXPR) out of the Growth Stock Strategist portfolio. The shriveling of mall traffic matched with a poor quarter of merchandising demolished estimates for the year. Earnings for this year are now $.98 versus $1.48 when… Read More
Today, we’re announcing the end of one of our newsletters, but not the end of our faith in emerging markets (though you may have given up on them a long time ago). It’s a faith we continue to champion in our Personal Finance newsletter as a key growth engine… Read More
We’re issuing a Stop Loss recommendation for SolarEdge at $16 for half your shares.Our reasoning: SolarEdge continues to trade lower despite beating estimates by $.04 Tuesday and issuing solid guidance. Revenue grew 27% and earnings were up 42%. Although 2017 estimates have come down since my original recommendation, the stock… Read More
Sometimes a short seller can’t catch a break. You’d think that a company’s stock would drop when it admits to the Federal Trade Commission that it’s been manipulating customers, will pay a $200 million fee and will enact draconian changes to its business to reduce this deception.But that’s the story of Herbalife,… Read More
- July 19, 2016
-
Download Issue
Air Transport Services GroupOn June 22 Air Transport (NSDQ: ATSG) bought 3.8 million shares from its largest shareholder for $13.07 per share, a 3% discount to the closing price. The shareholder, Red Mountain Capital, now owns 11.5% of Air Transport’s shares, down from 17.5% previously. Thanks to its strong… Read More